In a new era of medicine where health plans offer less and rising premiums are a safer bet than any investment strategy, medical cannabis has attracted many proponents and just as many adversaries. And, among the proponents of medical cannabis are adversaries of innovative cannabis products, such as Idrasil, who find Idrasil a threat to their personal financial stakes in the “Green Rush”.
One such critic of Idrasil, Dr. Allan Frankel, has benchmarked his knowledge and practice of cannabis based medicine on fringe theories offering no citations to any scientific studies for medically based claims made on his site. In a 2012 review of Idrasil, Dr. Frankel disputes the amount of active cannabinoids present in Idrasil tablets, but does not cite the findings of the two labs that he claims to have analyzed the tablets. While he correctly states that Idrasil boasts a significant amount of CBN in harmony with THC and CBD, he does not acknowledge the scientific properties of CBN as a sleep-aid or in promoting bone growth, and demonstrates a lack of understanding of current cannabidiol studies and medicinal benefits of each phytocannabinoid.
“Trends in Pharmacological Sciences”, Volume 30, Issue 10, October 2009, Pages 515-527, reviews the non-narcotic pain relieving properties of CBN in relation to other phytocannabinoids such as THC and CBD. Similarly, ignoring research, Dr. Frankel fails to acknowledge the lack of analgesic pain-relieving properties in CBD compared to CBN and THC as reviewed in“Analgesic and Antiinflamatory Activity of Constituents of Cannabis Sativa L”, Inflammation, Vol 12, No. 4, 1988.
Still, even other adversaries of Dr. Frankel and the CBD Conquistadors, question the validity of the over-accentuated CBD phytocannabinoid as the cure all to all ailments with benefits outweighing THC. ProjectCBD, an online news service dedicated to defending whole plant cannabis therapeutics through education, contends that many like Frankel on the CBD bandwagon ignore US sponsored research stating that CBD and THC interact synergistically and potentiate each other’s therapeutic effects as concluded in“Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants”. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8268-73. Why Dr. Frankel claims to not have felt the effects of THC or CBD after ingesting an Idrasil tablet, we would like to submit that we question the dosing that Dr. Frankel chose to illegally prescribe himself. Idrasil is titrated in a standardized and consistent dose administered by weight so that there are not any psychoactive effects of the pill. Therefore, Dr. Frankel’s claim to not feeling the effects of THC or CBD are consistent with the design of Idrasil as a daily regiment for long-term benefit.
While we question Dr. Frankel’s lack of judgement in his evaluations of Idrasil and not entertaining a proper discussion of its properties, we are not alone. The Medical Board of California revoked his license in 2010 and placed him on probation for five years pending a psych evaluation that deemed he suffered form a variety of psychiatric conditions which significantly interfered with his ability to process information, form judgements or relate to coherent history.
Under the terms of his probation, Dr. Frankel is currently not allowed to prescribe cannabis to patients and is ordered to abstain from the use of controlled substances including cannabis. Therefore, any claim that Dr. Frankel had possession or sampled Idrasil would have been a violation of his probation as it was not prescribed to him.
When Dr. Frankel officially finishes his probation, we hope that he will consider Idrasil as a standardized and consistent cannabis option for treating his diagnosis of narcissistic personality disorder.